title: [Predicting early response to immunosuppressive therapy in severe aplastic anemia by soluble transferrin receptor assay].
abstract: OBJECTIVE
  To evaluate the value of serum soluble transferrin receptor (sTfR) concentration in predicting early response to immunosuppressive therapy (IST) in severe aplastic anemia (SAA).
  
  
  METHODS
  Clinical data and hematologic responses of 140 SAA patients treated with rabbit antithymocyte globulin (rATG) combination with cyclosporine in our hospital were retrospectively analyzed. Correlation of pre-IST baseline of sTfR and IST responses was statistically analyzed and receiver operating characteristic (ROC) curve was used to estimate the sensitivity and specificity of sTfR in prediction of early responses.
  
  
  RESULTS
  Serum concentration of sTfR in very SAA (VSAA) patients were significantly lower than SAA and transfusion dependent non-SAA cases (P=0.001). The responders, especially at 3 months, had significantly higher pre- IST baseline of sTfR [median, 0.89 (range, 0.21-2.42) mg/L] than that [median, 0.58 (range, 0.13-1.88) mg/L] of non-responders (P=0.005). The cutoff level of 0.91 mg/L and 0.88 mg/L for predicting responses at 3 and 6 months were established based on the ROC curve, with the degree of accuracy of 65.0% and 60.7% respectively. Multivariate analysis showed that pre-IST baseline of sTfR was the independent factor of predicting response at 3 months (P=0.007) and at 6 months (P=0.021).
  
  
  CONCLUSIONS
  As a indicator of bone marrow failure severity, sTfR could predict early response to IST therapy in aplastic anemia.
authors: Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.
authors: Wen-rui
authors: WR
authors: Yang
authors: Yuan-yuan
authors: YY
authors: Xiong
authors: Li
authors: L
authors: Zhang
authors: Li-ping
authors: LP
authors: Jing
authors: Kang
authors: K
authors: Zhou
authors: Guang-xin
authors: GX
authors: Peng
authors: Yang
authors: Y
authors: Li
authors: Lei
authors: L
authors: Ye
authors: Yuan
authors: Y
authors: Li
authors: Jian-ping
authors: JP
authors: Li
authors: Hui-hui
authors: HH
authors: Fan
authors: Lin
authors: L
authors: Song
authors: Xin
authors: X
authors: Zhao
authors: Feng-kui
authors: FK
authors: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000628:therapy*; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D008875:Middle Aged; D011990:Receptors, Transferrin / Q000276:immunology / Q000627:therapeutic use*; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000961:Antilymphocyte Serum; D011990:Receptors, Transferrin; D016572:Cyclosporine